Author Topic: (Abst.) Health insurance affects the use of disease-modifying therapy in MS  (Read 67 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8568
  • MS diagnosed 1980
  • Location: Pacific Northwest
This is well known, of course, but interestingly some articles in medical journals are addressing the problem. The same issue of Neurology contains another article on the subject, "US Health Insurance Is an Obstacle to Disease-Modifying Treatments in MS," by D. Bourdette and F. Patti, but no abstract is available for it.

From PubMed, July 1, 2016:

Quote
Neurology. 2016 Jun 29.

Health insurance affects the use of disease-modifying therapy in multiple sclerosis

Wang G1, Marrie RA2, Salter AR2, Fox R2, Cofield SS2, Tyry T2, Cutter GR2.

Author information


1From the University of Alabama Birmingham (G.W., A.R.S., S.S.C., G.R.C.); University of Manitoba (R.A.M.), Winnipeg, Canada; Cleveland Clinic (R.F.), OH; and Dignity Health (T.T.), St. Joseph's Hospital and Medical Center, Phoenix, AZ. guoqiao@wustl.edu.

2From the University of Alabama Birmingham (G.W., A.R.S., S.S.C., G.R.C.); University of Manitoba (R.A.M.), Winnipeg, Canada; Cleveland Clinic (R.F.), OH; and Dignity Health (T.T.), St. Joseph's Hospital and Medical Center, Phoenix, AZ.

OBJECTIVE:

To evaluate the association between health insurance coverage and disease-modifying therapy (DMT) use for multiple sclerosis (MS).

METHODS:

In 2014, we surveyed participants in the North American Research Committee on MS registry regarding health insurance coverage. We investigated associations between negative insurance change and (1) the type of insurance, (2) DMT use, (3) use of free/discounted drug programs, and (4) insurance challenges using multivariable logistic regressions.

RESULTS:

Of 6,662 respondents included in the analysis, 6,562 (98.5%) had health insurance, but 1,472 (22.1%) reported negative insurance change compared with 12 months earlier. Respondents with private insurance were more likely to report negative insurance change than any other insurance.

Among respondents not taking DMTs, 6.1% cited insurance/financial concerns as the sole reason. Of respondents taking DMTs, 24.7% partially or completely relied on support from free/discounted drug programs. Of respondents obtaining DMTs through insurance, 3.3% experienced initial insurance denial of DMT use, 2.3% encountered insurance denial of DMT switches, and 1.6% skipped or split doses because of increased copay. For respondents with relapsing-remitting MS, negative insurance change increased their odds of not taking DMTs (odds ratio [OR] 1.50; 1.16-1.93), using free/discounted drug programs for DMTs (OR 1.89; 1.40-2.57), and encountering insurance challenges (OR 2.48; 1.64-3.76).

CONCLUSIONS:

Insurance coverage affects DMT use for persons with MS, and use of free/discounted drug programs is substantial and makes economic analysis that ignores these supplements potentially inaccurate. The rising costs of drugs and changing insurance coverage adversely affect access to treatment for persons with MS.

The abstract can be seen here.
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
204 Views
Last post February 06, 2017, 08:52:28 pm
by agate
0 Replies
44 Views
Last post March 01, 2017, 11:19:01 am
by agate
0 Replies
44 Views
Last post October 29, 2017, 03:38:47 pm
by agate
0 Replies
56 Views
Last post January 10, 2018, 04:41:40 pm
by agate
2 Replies
12 Views
Last post May 19, 2020, 08:56:17 pm
by agate